Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass
スポンサーリンク
概要
- 論文の詳細を見る
- 2007-10-15
著者
-
KALL Morten
Department of Early Development Pharmacokinetics, Drug Development ADME
-
FU Irong
Department of Drug Metabolism, Merck Research Laboratory
-
DIGE Tina
Department of Early Development Pharmacokinetics, Drug Development ADME
-
VALLANO Patrick
Department of Drug Metabolism, Merck Research Laboratory
-
WOOLF Eric
Department of Drug Metabolism, Merck Research Laboratory
-
JORGENSEN Martin
Department of Early Development Pharmacokinetics, Drug Development ADME
-
Fu Irong
Department Of Drug Metabolism Merck Research Laboratory
-
Woolf Eric
Department Of Drug Metabolism Merck Research Laboratory
-
Dige Tina
Department Of Early Development Pharmacokinetics Drug Development Adme
-
Jorgensen Martin
Department Of Early Development Pharmacokinetics Drug Development Adme
-
Kall Morten
Department Of Early Development Pharmacokinetics Drug Development Adme
-
Vallano Patrick
Department Of Drug Metabolism Merck Research Laboratory
-
Vallano Patrick
Department Of Chemistry Oregon State University
-
Woolf Eric
Department Of Clinical Pk/pd Merck Research Laboratories Merck & Co. Inc.
関連論文
- Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass
- A flexible and high throughput liquid chromatography-tandem mass spectrometric assay for the quantitation of telcagepant in human plasma
- Determination of sitagliptinin human plasma using protein precipitation and tandem mass spectrometry
- Affinity screening by packed capillary high-performance liquid chromatography using molecular imprinted sorbents : I. Demonstration of feasibility